Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction
-
- Justin T. Parizo
- Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California
-
- Jeremy D. Goldhaber-Fiebert
- Stanford Health Policy, Centers for Health Policy and Primary Care and Outcomes Research, The Freeman Spogli Institute, Department of Medicine, Stanford University, Stanford, California
-
- Joshua A. Salomon
- Stanford Health Policy, Centers for Health Policy and Primary Care and Outcomes Research, The Freeman Spogli Institute, Department of Medicine, Stanford University, Stanford, California
-
- Kiran K. Khush
- Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California
-
- John A. Spertus
- St Luke’s Mid America Heart Institute, University of Missouri–Kansas City
-
- Paul A. Heidenreich
- Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California
-
- Alexander T. Sandhu
- Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California
収録刊行物
-
- JAMA Cardiology
-
JAMA Cardiology 6 (8), 926-, 2021-08-01
American Medical Association (AMA)